BioCentury | Feb 23, 2021
Management Tracks

Genmab names Ahmadi CMO, head of experimental medicines; plus moves at Wugen and Aevitas

...developer Wugen Inc. hired Jan Davidson as CMO. Davidson was senior director for clinical research at MacroGenics Inc....
BioCentury | Dec 17, 2020
Deals

Dec. 16 Quick Takes: MacroGenics' margetuximab approved for breast cancer; plus sotorasib, Mesoblast, Cardior, Takeda, Allero

...for MacroGenics FDA approved Margenza margetuximab-cmkb from MacroGenics Inc....
...OBS) (TAK-721, SHP621) sotorasib (AMG 510) margetuximab (MGAH22) rexlemestrocel-l (MPC-300-IV) Cardior Pharmaceuticals Takeda Mesoblast Amgen MacroGenics Allero Abbreos covid-19...
BioCentury | Oct 1, 2020
Management Tracks

CVS’s Asgarian joins Thrive as CMO; plus Black Diamond names Ingram chairman and updates from MorphoSys, G1 and more

...Inc. as CMO. Rock was most recently clinical project leader and VP of clinical research at MacroGenics Inc....
BioCentury | Jul 17, 2020
Finance

Survey: biotechs adapting to COVID-19 era, optimistic about 2021

...people are concerned about,” da Silva said during the webinar. Scott Koenig , CEO of MacroGenics Inc....
...that said the question did not apply to them (see “API Supply”). Figure: API supply MacroGenics...
...between revenue-generating and pre-revenue companies (see “Survey Demographics”). Figure: Survey demographics Amanda Micklus, Senior Biopharma Analyst Immunocore Ltd. MacroGenics Inc. BeiGene...
BioCentury | Jul 7, 2020
Deals

Adding to targeted oncology portfolio, Zai gains China rights to Turning Point’s repotrectinib

...They include FGFR2b program bemarituzumab from Five Prime Therapeutics Inc. (NASDAQ:FPRX); HER2-targeting mAb margetuximab from MacroGenics Inc....
BioCentury | Jun 19, 2020
Management Tracks

Dubovsky succeeds Fries as Novavax CMO; plus Carl June to head Ziopharm SAB, Dewpoint, FerGene, Cambrex, Adverum, Epsilen and more

...June 29. Spellman was CFO and CBO at Intarcia Therapeutics Inc. Antibody cancer therapeutics company MacroGenics Inc....
...Oncology Inc. Dewpoint Therapeutics FerGene Inc. Adverum Biotechnologies Inc. Epsilen Bio s.r.l. Kaleido Biosciences Inc. Laboratory for Advanced Medicine Inc. Mundipharma International Ltd. MacroGenics Inc. BioXcel...
BioCentury | Jun 5, 2020
Finance

Founding investors MPM, F2 back Cullinan’s asset-centric approach with $98.5M series B

...financing, Cullinan announced the appointment of Jon Wigginton as CMO. He was previously CMO at MacroGenics Inc....
BioCentury | May 30, 2020
Product Development

May 29 ASCO Quick Takes: Investors sour on Arvinas’ targeted degraders; plus MacroGenics, Karyopharm, Blueprint

...led to two PSA responses among eight evaluable patients with metastatic castration-resistant prostate cancer (mCRPC). MacroGenics...
...antibody data Investors also weren’t very impressed with updated Phase I data for MGD013 from MacroGenics Inc....
...combination therapy with anti-HER2 mAb margetuximab showed a 50% response rate in six evaluable patients. MacroGenics...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

...HER2 and HER3 ( No. TS3654 ), the PD-1 x LAG3 bispecific antibody MDG013 from MacroGenics Inc....
BioCentury | May 23, 2020
Product Development

TIGIT breaks through as next-generation checkpoint target

...from a different LAG3 will be presented at ASCO. The bispecific, tetravalent antibody MGC018 from MacroGenics Inc....
Items per page:
1 - 10 of 237
BioCentury | Feb 23, 2021
Management Tracks

Genmab names Ahmadi CMO, head of experimental medicines; plus moves at Wugen and Aevitas

...developer Wugen Inc. hired Jan Davidson as CMO. Davidson was senior director for clinical research at MacroGenics Inc....
BioCentury | Dec 17, 2020
Deals

Dec. 16 Quick Takes: MacroGenics' margetuximab approved for breast cancer; plus sotorasib, Mesoblast, Cardior, Takeda, Allero

...for MacroGenics FDA approved Margenza margetuximab-cmkb from MacroGenics Inc....
...OBS) (TAK-721, SHP621) sotorasib (AMG 510) margetuximab (MGAH22) rexlemestrocel-l (MPC-300-IV) Cardior Pharmaceuticals Takeda Mesoblast Amgen MacroGenics Allero Abbreos covid-19...
BioCentury | Oct 1, 2020
Management Tracks

CVS’s Asgarian joins Thrive as CMO; plus Black Diamond names Ingram chairman and updates from MorphoSys, G1 and more

...Inc. as CMO. Rock was most recently clinical project leader and VP of clinical research at MacroGenics Inc....
BioCentury | Jul 17, 2020
Finance

Survey: biotechs adapting to COVID-19 era, optimistic about 2021

...people are concerned about,” da Silva said during the webinar. Scott Koenig , CEO of MacroGenics Inc....
...that said the question did not apply to them (see “API Supply”). Figure: API supply MacroGenics...
...between revenue-generating and pre-revenue companies (see “Survey Demographics”). Figure: Survey demographics Amanda Micklus, Senior Biopharma Analyst Immunocore Ltd. MacroGenics Inc. BeiGene...
BioCentury | Jul 7, 2020
Deals

Adding to targeted oncology portfolio, Zai gains China rights to Turning Point’s repotrectinib

...They include FGFR2b program bemarituzumab from Five Prime Therapeutics Inc. (NASDAQ:FPRX); HER2-targeting mAb margetuximab from MacroGenics Inc....
BioCentury | Jun 19, 2020
Management Tracks

Dubovsky succeeds Fries as Novavax CMO; plus Carl June to head Ziopharm SAB, Dewpoint, FerGene, Cambrex, Adverum, Epsilen and more

...June 29. Spellman was CFO and CBO at Intarcia Therapeutics Inc. Antibody cancer therapeutics company MacroGenics Inc....
...Oncology Inc. Dewpoint Therapeutics FerGene Inc. Adverum Biotechnologies Inc. Epsilen Bio s.r.l. Kaleido Biosciences Inc. Laboratory for Advanced Medicine Inc. Mundipharma International Ltd. MacroGenics Inc. BioXcel...
BioCentury | Jun 5, 2020
Finance

Founding investors MPM, F2 back Cullinan’s asset-centric approach with $98.5M series B

...financing, Cullinan announced the appointment of Jon Wigginton as CMO. He was previously CMO at MacroGenics Inc....
BioCentury | May 30, 2020
Product Development

May 29 ASCO Quick Takes: Investors sour on Arvinas’ targeted degraders; plus MacroGenics, Karyopharm, Blueprint

...led to two PSA responses among eight evaluable patients with metastatic castration-resistant prostate cancer (mCRPC). MacroGenics...
...antibody data Investors also weren’t very impressed with updated Phase I data for MGD013 from MacroGenics Inc....
...combination therapy with anti-HER2 mAb margetuximab showed a 50% response rate in six evaluable patients. MacroGenics...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

...HER2 and HER3 ( No. TS3654 ), the PD-1 x LAG3 bispecific antibody MDG013 from MacroGenics Inc....
BioCentury | May 23, 2020
Product Development

TIGIT breaks through as next-generation checkpoint target

...from a different LAG3 will be presented at ASCO. The bispecific, tetravalent antibody MGC018 from MacroGenics Inc....
Items per page:
1 - 10 of 237